Theranostics and precision medicine In neuroendocrine tumors
Open Access
- 1 December 2022
- journal article
- review article
- Published by University of Nis Faculty of Medicine in AFMN Biomedicine
- Vol. 40 (3) , 259-269
Abstract
Neuroendocrine tumors (NETs) have increased expression of somatostatin receptors (SSTR), where subtype 2 and 5 are the most common. Overexpression of the SSTR is an outstanding molecular target for inoperable and metastatic NETs that enables a unique approach of targeted diagnosis and treatment. In addition to SSTRs, neuroendocrine tumors also express other receptors that can be suitable targets for visualization by nuclear medicine methods. This review paper is focused on the most common radiopharmaceuticals and their molecular targets that are used today based on theranostic approach in NETs. In conventional nuclear medicine, the most important diagnostic radiopharmaceuticals are somatostatin analogs (SSA) labeled with 111 In and 99m Tc, however 99m Tc has advantages over 111 In based on better physical characteristics and better performance. In recent years, highly potent theranostic pairs have been created for the imaging and treatment of NETs, which can strongly bind SSTR. Derivatives of 68 Ga-labeled octreotide are recommended for diagnostics and follow-up of NENs. The great advantage of 68 Ga radiopharmaceuticals is that identical compounds can be labeled with therapeutic radionuclides 90 Y and 177 Lu. Peptide receptor radionuclide therapy is a systemic molecular target therapy that has proven to be safe and very effective in controlling the disease and prolonging the survival of patients with advanced and inoperable NETs. With a negligible number of adverse events, this therapy is safe and should be administered to all patients who meet the necessary criterias, primarily overexpression of the somatostatin receptor type 2.Keywords
This publication has 42 references indexed in Scilit:
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)Gut, 2011
- CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefactJournal of Clinical Pathology, 2005
- Technetium Labeled Bombesin-like Peptide: Preliminary Report on Breast Cancer Uptake in PatientsCancer Biotherapy and Radiopharmaceuticals, 2002
- Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignanciesSeminars in Nuclear Medicine, 2002
- In vitro and in vivo evaluation of new radiolabeled neurotensin(8–13) analogues with high affinity for NT1 receptorsNuclear Medicine and Biology, 2001
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotideNuclear Medicine Communications, 1998
- DOTATOC: A powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Visualization of the thymus by substance P receptor scintigraphy in manEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐OctreotideAnnals of the New York Academy of Sciences, 1994